A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma.
A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma.
复制标题
一组潜在的六长非编码 RNA 特征可改善弥漫性大 B 细胞淋巴瘤的生存预测
DOI：
10.1038/srep27842
复制
发表时间：
2016-06-13
影响因子：
4.6
通讯作者：
Zhou M
中科院分区：
文献类型：
--
作者：
Sun J;Cheng L;Shi H;Zhang Z;Zhao H;Wang Z;Zhou M
长链非编码rna （lncRNAs）代表了癌症生物学的一个新兴层面，并与癌症的发生和进展有关。然而，lncrna在弥漫性大b细胞淋巴瘤（DLBCL）中的预后意义尚不清楚，需要系统研究。在这项研究中，我们通过重新利用基因表达综合数据库（Gene expression Omnibus， GEO）中公开可用的微阵列数据集，获得并分析了1043名DLBCL患者的三个队列的lncRNA表达谱。在207例患者的发现系列中，我们使用单变量Cox回归分析确定了一组6个与患者总生存期（OS）显著相关的lncrna。将6个预后lncrna组合形成基于表达的6个lncrna特征，将发现系列患者分为高危组和低危组，生存结局存在显著差异（HR = 2.31, 95% CI = 1.8 ~ 2.965, p < 0.001）。在内部测试系列和另外两个不同阵列平台的独立数据集中进一步证实了6 - lncrna的特征。此外，6 - lncrna标记的预后价值与常规临床因素无关。功能分析表明，6 - lncrna可能通过在已知的癌症相关通路、免疫系统和信号分子相互作用中发挥调控作用，参与DLBCL。
Long non-coding RNAs (lncRNAs) represent an emerging layer of cancer biology and have been implicated in the development and progression of cancers. However, the prognostic significance of lncRNAs in diffuse large-B-cell lymphoma (DLBCL) remains unclear and needs to be systematically investigated. In this study, we obtained and analyzed lncRNA expression profiles in three cohorts of 1043 DLBCL patients by repurposing the publicly available microarray datasets from the Gene Expression Omnibus (GEO) database. In the discovery series of 207 patients, we identified a set of six lncRNAs that was significantly associated with patients’ overall survival (OS) using univariate Cox regression analysis. The six prognostic lncRNAs were combined to form an expression-based six-lncRNA signature which classified patients of the discovery series into the high-risk group and low-risk group with significantly different survival outcome (HR = 2.31, 95% CI = 1.8 to 2.965, p < 0.001). The six-lncRNA signature was further confirmed in the internal testing series and two additional independent datasets with different array platform. Moreover, the prognostic value of the six-lncRNA signature is independent of conventional clinical factors. Functional analysis suggested that six-lncRNA signature may be involved with DLBCL through exerting their regulatory roles in known cancer-related pathways, immune system and signaling molecules interaction.